0001867096-24-000041.txt : 20240401
0001867096-24-000041.hdr.sgml : 20240401
20240401174509
ACCESSION NUMBER: 0001867096-24-000041
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240315
FILED AS OF DATE: 20240401
DATE AS OF CHANGE: 20240401
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kong Garheng
CENTRAL INDEX KEY: 0001435183
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40880
FILM NUMBER: 24811370
MAIL ADDRESS:
STREET 1: 712 COLLEGE AVENUE
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Xeris Biopharma Holdings, Inc.
CENTRAL INDEX KEY: 0001867096
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 871082097
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
BUSINESS PHONE: 844-445-5704
MAIL ADDRESS:
STREET 1: 1375 WEST FULTON STREET, SUITE 1300
CITY: CHICAGO
STATE: IL
ZIP: 60607
4
1
wk-form4_1712007900.xml
FORM 4
X0508
4
2024-03-15
0
0001867096
Xeris Biopharma Holdings, Inc.
XERS
0001435183
Kong Garheng
C/O XERIS BIOPHARMA HOLDINGS, INC.
1375 WEST FULTON STREET, SUITE 1300
CHICAGO
IL
60607
1
0
0
0
0
Common Stock
2024-03-15
4
J
0
6474
A
114144
D
Keveyis Sales 2023 Milestone achieved resulting in the settlement of the related Contingent Value Right ("CVR") in shares of Xeris Biopharma Holdings, Inc. (the "Company")'s Common Stock.
The reporting person's right to receive additional shares pursuant to this earn-out right became fixed and irrevocable on October 5, 2021, the effective time of the Merger (as defined below), pursuant to the transaction agreement dated as of May 24, 2021 by and among Xeris Pharmaceuticals, Inc. ("Xeris"), Strongbridge Biopharma plc ("Strongbridge"), the Issuer ("HoldCo") and Wells MergerSub, Inc., a wholly owned subsidiary of HoldCo ("MergerSub"), where HoldCo acquired the entire issued and to be issued ordinary share capital of Strongbridge, and MergerSub merged with and into Xeris, with Xeris continuing as the surviving corporation and wholly owned subsidiary of HoldCo (the "Merger").
The number of shares of Common Stock for the CVR is equal to the product (A) $0.25 divided by the volume weighted average price for the Company's Common Stock as reported by
Nasdaq for the ten (10) Trading Days immediately prior to October 5, 2021 and (B) the number of CVRs held by the holder as reflected on the CVR Register.
/s/ Beth Hecht, as Attorney-in-Fact
2024-04-01